Compare Quest Diagnostics Inc (DGX) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs General Motors Company — how do they compare? Quest Diagnostics Inc trades at $237.21 (market cap $26.21B), while General Motors Company trades at $87.22 (market cap $78.40B). The key difference: General Motors Company is far larger — about 3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | GM | |
|---|---|---|
Market Cap | $26.21B | $78.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $90.30 |
52-Week Low | $173.49 | $54.16 |
Enterprise Value | $31.97B | $181.38B |
Dividend Yield | 1.45% | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
General Motors (GM) trades at $87.74, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company has demonstrated consistent earnings outperformance, beating estimates in the last three quarters. Recent strategic moves include a $4.5 billion parts supply deal and extending its China joint venture for 20 years. Valuation metrics show attractive P/S and P/B ratios, though profitability margins remain thin with net income margin at 1.05%.
GM presents a compelling investment case with analyst consensus pointing to 24% upside to the $108.82 price target. Strong cash flow generation and strategic partnerships support growth prospects, but investors face risks from declining profit margins, rising debt levels, and automotive industry cyclicality. The stock's current technical positioning near key support levels suggests potential for near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
